HTBX Heat Biologics Inc.

0.54
+0.04  (+7%)
Previous Close 0.5
Open 0.51
Price To Book 3.18
Market Cap 42,867,371
Shares 79,384,021
Volume 8,617,511
Short Ratio
Av. Daily Volume 16,220,874
Stock charts supplied by TradingView

NewsSee all news

  1. Heat Biologics Announces Formation of COVID-19 Advisory Board

    DURHAM, NC / ACCESSWIRE / April 1, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines,

  2. Heat Biologics Provides Year-End Business Update

    Provides update on development of gp96 vaccine for preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19Reports progress on development of COVID-19 30-minute point of care diagnostic test Completed

  3. Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreement

    Test being designed to provide rapid, point-of-care diagnosis within 30 minutesDURHAM, NC / ACCESSWIRE / March 23, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company

  4. Heat Biologics Invited to Join The Alliance for Biosecurity

    DURHAM, NC / ACCESSWIRE / March 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines including one for

  5. Heat Biologics, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City

    NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data presented at AACR November 19, 2019 noted ORR of 20% (RECIST 1.1).
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)
Phase 1 initiation of dosing announced December 16, 2019. Initial data due 2020.
HS-130
Solid tumors

Latest News

  1. Heat Biologics Announces Formation of COVID-19 Advisory Board

    DURHAM, NC / ACCESSWIRE / April 1, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of novel therapeutic and prophylactic vaccines,

  2. Heat Biologics Provides Year-End Business Update

    Provides update on development of gp96 vaccine for preventing infection from the SARS-CoV-2 coronavirus that causes COVID-19Reports progress on development of COVID-19 30-minute point of care diagnostic test Completed

  3. Heat Biologics and University of Miami Developing Proprietary COVID-19 Diagnostic Test Under Collaborative Research Agreement

    Test being designed to provide rapid, point-of-care diagnosis within 30 minutesDURHAM, NC / ACCESSWIRE / March 23, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company

  4. Heat Biologics Invited to Join The Alliance for Biosecurity

    DURHAM, NC / ACCESSWIRE / March 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines including one for

  5. Heat Biologics, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City

    NEW YORK, NY / ACCESSWIRE / March 5, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate

  6. Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus

    Heat's gp96 vaccine platform activates CD8 T cells, antigen presenting cells and natural killer cells, and induces mucosal immunity which could make it an ideal vaccine for COVID-19Vaccine designed to induce a

  7. Heat Biologics CEO to Appear Today on ABC11-WTVD to Discuss the Company's Newly Launched Program to Develop a Vaccine to Protect Against SARS-CoV-2 Coronavirus that Causes COVID-19

    DURHAM, NC / ACCESSWIRE / March 4, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines, today announced that

  8. Heat Biologics, Inc. Announces Closing of $7,000,000 Public Offering

    DURHAM, NC / ACCESSWIRE / January 21, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate

  9. Heat Biologics, Inc. Prices $7,000,000 Public Offering

    DURHAM, NC / ACCESSWIRE / January 16, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company specializing in the development of therapeutics designed to activate

  10. Heat Biologics Announces First Patient Dosed in the First Phase 1 Trial of HS-130

    First allogeneic, off-the-shelf cell therapy approach that enhances T-cell activation through localized OX40-mediated co-stimulation of dormant immune signalsDURHAM, NC / ACCESSWIRE / December 16, 2019 / Heat Biologics,

  11. Heat Biologics Announces Additional Positive Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients

    Prospectively Defined PD-L1 Positive Patients Achieved Median Overall Survival of 42 MonthsDURHAM, NC / ACCESSWIRE / November 20, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), presented additional positive Phase 2 interim

  12. Heat Biologics Announces Additional Top Line Phase 2 Data of HS-110 plus Nivolumab in Advanced NSCLC Patients at AACR Tumor Immunology and Immunotherapy Conference

    DURHAM, NC / ACCESSWIRE / November 18, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced

  13. Heat Biologics Reports Third Quarter 2019 Results and Provides Corporate Update

    Reported Positive Phase 2 Interim Data in Advanced Non-Small Cell Lung Cancer PatientsMORRISVILLE, NC / ACCESSWIRE / November 15, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  14. Heat Biologics Presents Additional Phase 2 Interim Data in Advanced NSCLC Patients at the SITC 34th Annual Meeting

    Promising results in patients whose disease has progressed after checkpoint inhibitor therapyDURHAM, NC / ACCESSWIRE / November 11, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a biopharmaceutical company developing

  15. Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment

    Announces Abstract Summarizing Favorable Interim Phase 2 Data of HS-110 Plus NivolumabAdditional Data to be Reported in Poster Presentation at the SITC 34th Annual Meeting on November 8, 2019DURHAM, NC / ACCESSWIRE /